We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Intermediate Capital Group Plc | LSE:ICP | London | Ordinary Share | GB00BYT1DJ19 | ORD 26 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2,124.00 | 2,128.00 | 2,130.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Security Brokers & Dealers | 737.1M | 280.6M | 0.9801 | 21.67 | 6.08B |
Date | Subject | Author | Discuss |
---|---|---|---|
22/5/2019 09:10 | Dividend increase says it all re future prospects here. | its the oxman | |
16/5/2019 16:11 | Finals on 22nd which should be good from what they said in January (3rd Qtr) 2018 AR: | mirandaj | |
16/5/2019 14:14 | Results imminent and touching c.1200p | its the oxman | |
13/4/2019 11:19 | Starts: Intermediate Capital Group’s Europe VII Fund is pleased to announce it has, in partnership with Mérieux Equity Partners and DOC Generici’s management team, agreed to invest in DOC Generici, one of Italy’s largest independent generic pharmaceutical companies - subject to antitrust approval . DOC Generici provides drugs for the treatment of common medical conditions with a broad product portfolio and a strong presence in areas including cardiovascular, gastrointestinal/met This is the seventh deal for the Europe VII fund, which provides long term financing for growing private companies across Europe. The fund closed with €4.5bn of commitments in November 2018. Luigi Bartone, Head of Italian Subordinated Debt & Equity Investments, said: “DOC Generici exhibits the classic characteristics we look for in an investment. The company is well established, highly cash generative, and led by a best-in class, committed management team. It benefits from a resilient and growing market driven by the ongoing penetration of generics in the Italian pharmaceutical market. We believe there are significant opportunities to continue to grow the business, and ICG resources and global networks will support management’s and Mérieux&rsquo | mirandaj | |
05/4/2019 16:01 | Hoping to see 1200p plus again come results if wider market stays strong. | its the oxman | |
03/4/2019 18:53 | Nearly 5% jump up today, no obvious reason. Results due 22 May. | pvb | |
29/1/2019 09:00 | Excellent TU today continuing good performance. | deadly | |
20/11/2018 00:48 | ...the share price will "fluctuate". | pvb | |
19/11/2018 11:20 | Updated price targets / forecasts anyone ? | its the oxman | |
15/11/2018 23:45 | Interim results: | pvb | |
05/11/2018 18:12 | Shudda taken the advice! :-) | pvb | |
29/8/2018 11:39 | Has anyone read the Shore Capital "Sell" recommendation of 26 July 2018? I'd like to know what they said. Thanks. | mrtenpercent | |
26/7/2018 12:57 | Good results I'd say, recent falls not justified: * Inflows in the first quarter were €4.8bn. 2018/19 fundraising is weighted to the first quarter of the financial year; €3.7bn has been raised for Europe Fund VII * Total AUM 15% higher at €32.9bn and third party fee earning AUM 20% higher at €25.2bn *Fund deployment remains strong across strategies *All funds on course to meet or exceed their return hurdle rates | deadly | |
22/6/2018 08:10 | Top up time again 1100p - expecting further positive newsflow here. | its the oxman | |
14/6/2018 08:48 | X div today and down to 1130p | its the oxman | |
22/5/2018 18:08 | All going nicely. | topvest | |
22/5/2018 14:27 | Final results: "The strength of our fund management business allows the Board to recommend an 11% increase in the full year dividend." Yum. | pvb | |
22/5/2018 08:41 | My goodness. And I thought I was such a clever clogs when I sold these on a spike up to 670p a couple of years ago [long sigh]. | speedsgh | |
22/5/2018 08:32 | Took a tiny bit of profit c.1200p but looks all set to push higher. | its the oxman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions